Sobi and Innate Pharma Finalize Strategic Lacutamab Partnership
After clearing mandatory antitrust reviews, Swedish Orphan Biovitrum and Innate Pharma have officially activated their strategic partnership. The deal centers on the development of lacutamab, with the companies now set to initiate a pivotal Phase 3 confirmatory study for patients suffering from cutaneous T-cell lymphoma.
The partnership, first announced on August 10, 2026, paves the way for the TELLOMAK-3 clinical trial. This study is essential for pursuing accelerated approval of the drug in cases of Sézary syndrome, a rare subtype of cutaneous T-cell lymphoma. Innate Pharma will lead the trial, while Sobi secures exclusive global commercialization rights upon potential approval. Should the Phase 3 results prove positive, Sobi retains the option to assume full global development authority.
Financial terms of the agreement include a 75 million USD payment to Innate Pharma upon the partnership’s effective date. The agreement further outlines up to 40 million USD in near-term development milestones linked to Sézary syndrome, with an additional 465 million USD tied to future regulatory and commercial successes. Beyond these payments, Innate stands to receive tiered double-digit royalties on net sales, marking a significant expansion of the company's oncology pipeline through this collaboration.
Comments (0)
No comments yet. Be the first!